Baxfendy was approved in the US for hypertension in adults not adequately controlled on other antihypertensive medicines. The approval was based on Phase III BaxHTN results showing significant systolic blood pressure reductions.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05766839 |
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age |
RECRUITING | PHASE2 |
